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Have been ignored in medical care and clinical trials,but need to be studied
S
ince a patient or a clinical trial participant is
connected to other people through social
network ties,medical interventions delivered to a
patient, quite apart from their health effects in that
person, may have unintended health effects in others
to whom he is connected. The cumulative impact of an
intervention is therefore the sum of the direct health
outcomes in the patient plus the collateral health out-
comes in others (figure). These effects, in both the
patient and in their social contacts,might be positive or
negative. Doctors, trialists, patients, or policy makers
might see reason to take them into account when
choosing treatment or evaluating benefit.
For example, treating depression in parents may
increase their propensity to vaccinate their children,
thereby saving children’s lives. Replacing a hip or pre-
venting a stroke may mean that a person is better able
to care for his spouse, thus improving her health.
Delivering a weight loss intervention to one person
may trigger substantial weight loss in that person’s
friends. Giving a patient superior end of life care may
decrease the stressfulness of the patient’s death and
thus decrease his spouse’s propensity to die during
bereavement.
1
These collateral health consequences that accrue to
others are known to social scientists as externalities.
They are similar to the increase in value a person’s
neighbour may see if the person refurbishes his prop-
erty; the person himself derives no benefit from the
neighbour’s windfall, even though he has invested
resources and created this new value. Here, however,
we are considering not monetary externalities but
rather specifically health externalities. Moreover, in the
healthcare arena patients may derive value from such
effects. For example, since 89% of patients feel that a
good death involves not burdening family,
2 patients
might prefer hospice care over standard terminal care
if they felt it offered health benefits to their loved ones.
1
When the cost-benefit assessment is made by
policy makers with a collective viewpoint, all the down-
stream costs and benefits of health care accruing to a
group might be relevant,and the argument in favour of
accounting for collateral effects might be even more
compelling than that perceived by individual doctors
or patients. From a societal perspective the assessment
of the cost effectiveness of medical interventions might
change substantially if the benefits of an intervention
are seen as including the collateral positive effects and
the costs as including the collateral negative effects.
Such a concern for collateral effects could,
however, also lead to unexpected results. For example,
preventing a death from heart attack, which is clearly
desirable from the individual’s perspective, may mean
that we have to forego the motivation that would
otherwise have accrued to others to whom the patient
is connected to improve their own health habits.
Another provocative implication is that policy makers
might value socially connected individuals—such as
married people—more when it comes to health care
since benefits might be multiplicative in such people.
3
We have scattered evidence supporting the
plausibility and likely magnitude of such collateral
health effects.The most well known example is that the
death of one spouse increases the risk of death in the
other.
45 Moreover, morbidity in one spouse can
contribute to morbidity in the other—for example, via
caregiver burden.
6 Breast cancer in one woman may
motivate others to whom she is connected to have
mammography.
7 Exercise or smoking cessation in one
person may prompt numerous others to behave
similarly. Conversely, there may be epidemics of disor-
ders such as obesity, alcoholism, suicide, or depression
that might spread in a peer to peer fashion.
8 Even loose
social connections can be conduits for such effects;
cancer in a celebrity, for example, may motivate many
people not known to the index case to undergo cancer
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Collateral health effects of medical care in social networks. In the conventional perspective on medical care, the benefits and costs of health
care are judged by the way in which they help to achieve a direct, intended outcome in a patient. However, since a patient is connected to
others through social ties, health care delivered to one person, quite apart from its health effects on that person, may have health effects on
others. The cumulative impact of the intervention is therefore a sum of the direct outcomes in the patient plus the collateral outcomes in
others. These outcomes may be both positive and negative in both the patient and in his or her social contacts (for example, side effects of
medication in the individual, herd immunity in social contacts). Attention to, and measurement of, the existence of unintended outcomes
arising out of the embeddedness of patients in social networks can prompt a rethinking of the relative value of healthcare interventions or of
the conduct of clinical trials.
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91 0Vaccinat-
ing some people in a population may cause others (for
example, immunocompromised people) to become
sick through the spread of the vaccine virus or,
conversely, to remain well through the effect of herd
immunity.
The existence of collateral health effects and the
fact that each individual may be connected to
numerous others, including relatives, friends, neigh-
bours, and co-workers, implies developments in
research and policy. To explore such effects, new data-
sets and methods will be needed. Most prospective
cohort studies and randomised controlled trials today
include only individuals who are followed to observe
outcomes. Some social science and epidemiological
cohort studies do ask individuals about the health sta-
tus of their spouse or some other social contact, but
only a few (for example, the US health and retirement
survey) actually include the spouse or other social con-
tacts in the study cohort.Developing datasets with such
features and measurements is necessary to understand
fully collateral health effects. Collecting information
about the various contacts of people enrolled in
clinical trials or epidemiological studies may represent
an extension to study design similar to the extension in
the 1990s of including cost effectiveness analyses as a
standard feature of clinical trials.
Network phenomena are receiving increased atten-
tion in fields as diverse as engineering, biology, and
sociology,
11 12 but they are also relevant to health and
medicine. Networks have emergent properties not
explained by the constituent parts and not present in
the parts. Understanding such properties requires
seeing whole groups of individuals and their
interconnections at once. The existence of social
networks means that people and events are interde-
pendent and that health and health care can transcend
the individual in ways that patients, doctors, policy
makers, and researchers should care about.
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Condoms and prevention of HIV
Are essential and effective,but additional methods are also needed
P
romotion of condoms has been a mainstay of
HIV prevention policy. Over the past few years,
however,the value and effectiveness of condoms
have increasingly been called into question. The grow-
ing “abstinence only” movement in the United States
questions the provision of condoms as part of the
policy and messaging of the US Agency for
International Development (USAID) and claims that
condoms have had little to do with the successes
achieved in reducing HIV in countries such as
Uganda.
1–2 Senior officials in the Roman Catholic
Church also continue to argue about the morality of
condom use and dispute its efficacy.
3
But what does the evidence tell us? A recent review
from the National Institutes for Health says that
condoms are protective against HIV infection,
4 reduc-
ing the probability of HIV transmission per sex act by
as much as 95% and reducing the annual HIV
incidence in serodiscordant couples by 90-95% when
used consistently.
5 However, the impact of inconsistent
use of condoms is less substantial: a meta-analysis
found that condom use of variable consistency among
serodiscordant couples reduced the annual HIV
incidence by 69%.
6 This illustrates how the protection
provided by a condom is dependent both on its
efficacy against HIV transmission per sex act and the
consistency with which it is used. This is intuitive, yet
the consistency of condom use is less commonly
factored into scientific and policy debate.
Evidence from around the world highlights the
extent to which patterns of condom use are influenced
by the form of partnership in which they are being
used. Interventions can achieve substantial increases in
the use of condoms in commercial and casual sex part-
nerships. Several studies report high levels of condom
use after interventions in commercial sex.
7–9 But even
in settings where HIV infection is widespread, the use
of condoms in primary partnerships remains low—
representative surveys of women in 13 African
countries found that fewer than 7% report condom use
in the last sex act with their regular partner.
10 Surveys
of sex workers in Asia generally find that, although
many use condoms with their clients, fewer than 40%
report using condoms in their last non-commercial sex
act. Unless one partner knows they are HIV positive or
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